MarketCap
Facebook
X
Telegram
Vanda Pharmaceuticals EBITDA | VNDA
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Vanda Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -150 M | -39.8 M | -13 M | 7.55 M | 43.5 M | 28.6 M | 24.3 M | 23.3 M | -15.2 M | -7.64 M | -27.2 M | -55.3 M | -18.9 M | -26.7 M | -9.21 M | 9.17 M | -35.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 43.5 M | -150 M | -15.4 M |
Quarterly EBITDA Vanda Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.5 M | -61.8 M | -48.2 M | -38.6 M | -29.5 M | -36.8 M | -39.3 M | -8.53 M | -9.25 M | -8.39 M | -7.22 M | -6.14 M | -5.62 M | -2.49 M | 2.38 M | 7.01 M | 4.29 M | 3.84 M | -7.29 M | 9 M | 11.2 M | 12.7 M | 10.7 M | 10.8 M | 8.11 M | 9.54 M | 245 K | 4.61 M | 11.1 M | 10.3 M | -1.71 M | 9.53 M | 6.63 M | 4.31 M | 2.79 M | -1.72 M | -4.49 M | -1.49 M | -7.45 M | 1.45 M | 2.29 M | -1.85 M | -9.53 M | -12 M | -6.6 M | -2.52 M | -6.15 M | 70.2 M | -912 K | -21 M | -26 M | -7.41 M | -5.05 M | -3.04 M | -4.2 M | -6.05 M | -5.02 M | -7.71 M | -7.95 M | -5.53 M | -2.92 M | -1.14 M | 84 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70.2 M | -61.8 M | -4.39 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sierra Oncology
SRRA
|
-94.3 M | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-8.95 M | $ 1.03 | -6.33 % | $ 11.6 M |  USA |
 |
Atea Pharmaceuticals
AVIR
|
-180 M | $ 4.24 | -3.97 % | $ 346 M | USA |
 |
Nektar Therapeutics
NKTR
|
-139 M | $ 37.82 | -0.01 % | $ 638 M | USA |
 |
Vaccinex
VCNX
|
-18.6 M | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-4.28 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-35.9 M | $ 1.05 | -3.24 % | $ 242 M | USA |
 |
Jounce Therapeutics
JNCE
|
-50.2 M | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
-154 M | - | - | $ 69.7 B |  Britain |
 |
Corner Growth Acquisition Corp.
COOL
|
-1.99 M | - | -0.89 % | $ 114 M | USA |
 |
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 7.0 | -8.62 % | $ 471 B | Britain |
 |
Mersana Therapeutics
MRSN
|
1.63 M | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-101 M | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-96.7 M | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
6.57 B | $ 54.08 | -3.08 % | $ 3.5 B |  Danmark |
 |
Allakos
ALLK
|
-115 M | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-19.2 M | - | - | $ 717 K | USA |
 |
Immuron Limited
IMRN
|
-5.34 M | $ 0.9 | 2.27 % | $ 208 M |  Australia |
 |
G1 Therapeutics
GTHX
|
-39 M | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M | Britain |
 |
BioVie
BIVI
|
-22.5 M | $ 1.25 | -3.85 % | $ 9.06 M | USA |
 |
Kinnate Biopharma
KNTE
|
-120 M | - | - | $ 123 M | USA |
 |
Mustang Bio
MBIO
|
-2.4 M | $ 0.44 | 12.95 % | $ 2.16 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-442 M | - | - | $ 7.29 B | USA |
 |
NexImmune
NEXI
|
-31.9 M | - | 70.13 % | $ 4.12 M | USA |
 |
Codexis
CDXS
|
-36.5 M | $ 1.0 | -9.91 % | $ 87.1 M | USA |
 |
Theravance Biopharma
TBPH
|
21.5 M | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Compugen Ltd.
CGEN
|
31.8 M | $ 2.06 | -3.72 % | $ 192 M |  Israel |
 |
IMV
IMV
|
-10.9 M | - | - | $ 13.1 M | Canada |
 |
Sanofi
SNY
|
6.34 B | $ 48.23 | 0.22 % | $ 58.9 B |  France |
 |
Karuna Therapeutics
KRTX
|
-493 M | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
-96.5 M | - | - | $ 756 M | USA |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-38.4 M | - | - | $ 229 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-14.6 M | $ 0.38 | -5.06 % | $ 4.68 B | Israel |
|
89bio
ETNB
|
-385 M | - | - | $ 1.55 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-97.9 M | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
-132 M | - | 0.42 % | $ 213 M | USA |
 |
Harpoon Therapeutics
HARP
|
-66 M | - | - | $ 763 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-48.7 M | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
-4.32 M | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
5.25 M | - | - | $ 109 M | USA |
 |
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
-48.8 M | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-29.5 M | - | 17.91 % | $ 11.1 M | USA |
 |
Seagen
SGEN
|
-566 M | - | - | $ 42.2 B | USA |
|
Protara Therapeutics
TARA
|
-64.2 M | $ 2.44 | -2.59 % | $ 105 M | USA |